Literature DB >> 25855180

Abnormal excitability and episodic low-frequency oscillations in the cerebral cortex of the tottering mouse.

Samuel W Cramer1, Laurentiu S Popa1, Russell E Carter1, Gang Chen1, Timothy J Ebner2.   

Abstract

The Ca(2+) channelopathies caused by mutations of the CACNA1A gene that encodes the pore-forming subunit of the human Cav2.1 (P/Q-type) voltage-gated Ca(2+) channel include episodic ataxia type 2 (EA2). Although, in EA2 the emphasis has been on cerebellar dysfunction, patients also exhibit episodic, nonmotoric abnormalities involving the cerebral cortex. This study demonstrates episodic, low-frequency oscillations (LFOs) throughout the cerebral cortex of tottering (tg/tg) mice, a widely used model of EA2. Ranging between 0.035 and 0.11 Hz, the LFOs in tg/tg mice can spontaneously develop very high power, referred to as a high-power state. The LFOs in tg/tg mice are mediated in part by neuronal activity as tetrodotoxin decreases the oscillations and cortical neuron discharge contain the same low frequencies. The high-power state involves compensatory mechanisms because acutely decreasing P/Q-type Ca(2+) channel function in either wild-type (WT) or tg/tg mice does not induce the high-power state. In contrast, blocking l-type Ca(2+) channels, known to be upregulated in tg/tg mice, reduces the high-power state. Intriguingly, basal excitatory glutamatergic neurotransmission constrains the high-power state because blocking ionotropic or metabotropic glutamate receptors results in high-power LFOs in tg/tg but not WT mice. The high-power LFOs are decreased markedly by acetazolamide and 4-aminopyridine, the primary treatments for EA2, suggesting disease relevance. Together, these results demonstrate that the high-power LFOs in the tg/tg cerebral cortex represent a highly abnormal excitability state that may underlie noncerebellar symptoms that characterize CACNA1A mutations.
Copyright © 2015 the authors 0270-6474/15/355664-16$15.00/0.

Entities:  

Keywords:  calcium channelopathy; cerebral cortex; episodic ataxia type 2; episodic nervous system dysfunction; flavoprotein optical imaging; tottering mouse

Mesh:

Substances:

Year:  2015        PMID: 25855180      PMCID: PMC4388925          DOI: 10.1523/JNEUROSCI.3107-14.2015

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  99 in total

1.  Nitric oxide modulates Ca(2+) channels in dorsal root ganglion neurons innervating rat urinary bladder.

Authors:  N Yoshimura; S Seki; W C de Groat
Journal:  J Neurophysiol       Date:  2001-07       Impact factor: 2.714

2.  Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension.

Authors:  K J Smith; P A Felts; G R John
Journal:  Brain       Date:  2000-01       Impact factor: 13.501

Review 3.  Cellular mechanisms of epilepsy: a status report.

Authors:  M A Dichter; G F Ayala
Journal:  Science       Date:  1987-07-10       Impact factor: 47.728

4.  Developmental expression of neuronal nitric oxide synthase in P/Q-type voltage-gated calcium ion channel mutant mice, leaner and tottering.

Authors:  Tamy C Frank-Cannon; Daniel R Zeve; Louise C Abbott
Journal:  Brain Res       Date:  2005-12-15       Impact factor: 3.252

5.  Bidirectional alterations in cerebellar synaptic transmission of tottering and rolling Ca2+ channel mutant mice.

Authors:  Kaori Matsushita; Minoru Wakamori; Im Joo Rhyu; Tatsuo Arii; Sen-Ichi Oda; Yasuo Mori; Keiji Imoto
Journal:  J Neurosci       Date:  2002-06-01       Impact factor: 6.167

6.  Familial episodic ataxia: clinical heterogeneity in four families linked to chromosome 19p.

Authors:  R W Baloh; Q Yue; J M Furman; S F Nelson
Journal:  Ann Neurol       Date:  1997-01       Impact factor: 10.422

7.  Aberrant expression of GABAA receptor subunits in the tottering mouse: an animal model for absence seizures.

Authors:  M H Tehrani; B J Baumgartner; S C Liu; E M Barnes
Journal:  Epilepsy Res       Date:  1997-10       Impact factor: 3.045

Review 8.  Primary episodic ataxias: diagnosis, pathogenesis and treatment.

Authors:  J C Jen; T D Graves; E J Hess; M G Hanna; R C Griggs; R W Baloh
Journal:  Brain       Date:  2007-06-15       Impact factor: 13.501

9.  Three syndromes produced by two mutant genes in the mouse. Clinical, pathological, and ultrastructural bases of tottering, leaner, and heterozygous mice.

Authors:  H Meier; A D MacPike
Journal:  J Hered       Date:  1971 Sep-Oct       Impact factor: 2.645

10.  Clinical spectrum of episodic ataxia type 2.

Authors:  J Jen; G W Kim; R W Baloh
Journal:  Neurology       Date:  2004-01-13       Impact factor: 9.910

View more
  2 in total

Review 1.  Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies.

Authors:  Julia Oyrer; Snezana Maljevic; Ingrid E Scheffer; Samuel F Berkovic; Steven Petrou; Christopher A Reid
Journal:  Pharmacol Rev       Date:  2018-01       Impact factor: 25.468

2.  Altered levels of the splicing factor muscleblind modifies cerebral cortical function in mouse models of myotonic dystrophy.

Authors:  Gang Chen; Russell E Carter; John D Cleary; Tammy S Reid; Laura P Ranum; Maurice S Swanson; Timothy J Ebner
Journal:  Neurobiol Dis       Date:  2018-01-10       Impact factor: 5.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.